Drugs Made In America Acquisition Corp.

Drugs Made In America Acquisition Corp. (Nasdaq: DMAAR) is a blank-check company formed to pursue a merger or acquisition in the pharmaceutical and domestic drug-manufacturing sector. The SPAC filed an amended registration statement on Form S-1/A with the SEC on November 7, 2024, indicating it was completing its IPO process at that time, with a planned listing on Nasdaq. The vehicle's name signals an explicit focus on U.S.-based pharmaceutical companies, a segment drawing increased policy and investor attention amid domestic drug-supply concerns. For the full sponsor profile, filing history, and deal timeline on DMAAR, sign up for complete data access at SpacDesk.